特比萘芬治疗糖尿病患者甲真菌病疗效和对血糖水平的影响  

Efficacy and influence on the blood glucose when treated with terbinafine for onychomycosis in patients with diabetes mellitus

作　　者：谢志宏[1] 姚志远[2] 李邻峰[3] 刘永生[4] 孙秋宁[5] 郑占才[2] 尤立平[2] 马蕾[2] 宋佩华[2] 

机构地区：[1]北京医院皮肤科,北京100730 [2]中日友好医院皮肤科,北京100029 [3]北京大学第三医院皮肤科,北京100083 [4]北京友谊医院皮肤科,北京100050 [5]北京协和医院皮肤科,北京100730

出　　处：《中国麻风皮肤病杂志》2007年第9期773-775,共3页China Journal of Leprosy and Skin Diseases

摘　　要：目的:评价特比萘芬连续疗法治疗糖尿病患者甲真菌病的有效性、安全性、耐受性和对患者血糖水平的影响。方法:90例糖尿病甲真菌病患者口服特比萘芬250mg,每日1次,指甲癣患者连续口服12周,趾甲癣患者连续口服16周;停药第24周观察最终疗效和血糖水平。结果:在第36周时,指甲真菌病的临床治愈率84.8%,有效率90.9%,真菌学治愈率93.9%;第40周时,趾甲真菌病的临床治愈率78.9%,有效率87.7%,真菌学治愈率89.5%;治疗前后空腹血糖和糖化血红蛋白水平无显著性差异。结论:特比萘芬治疗糖尿病患者甲真菌病有效、安全,耐受性良好;对患者血糖水平无明显影响。Objective： To evaluate the efficacy, safety, tolerability and the influence on the blood glucose when treated with continuous terbinafine for onychomycosis in patients with diabetes mellitus. Methods： Ninety patients with diabetes mellitus were treated with oral terbinafine 250 mg daily for 12 weeks for fingernail onychomycosis and 16 weeks for toenail onychomycosis. The global efficacy and the blood sugar were evaluated in 36 and 40 weeks after treatment respectively. Results： In 36 weeks, the clinical cure rate, clinical response rate and mycology clearance rate were 84.8%, 90.9% and 93.9% respectively for nail onychomycosis, and 78.9% ,87.7% and 89.5% respectively for toenail onychomycosis. Conclusion： Terbinafine is safe, effective and well tolerated, and no influence on blood glucose for onychomycosis in patients with diabetes mellitus.

关 键 词：特比萘芬 甲真菌病 糖尿病 血糖 

分 类 号：R587.1[医药卫生—内分泌] R756[医药卫生—内科学]